Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ulrich Kronthaler, Cornelius Fritsch, Otmar Hainzl, Andreas Seidl & Antonio da Silva. (2018) Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications. Expert Opinion on Biological Therapy 18:8, pages 921-930.
Read now
Read now
Tommaso Gabbani, Simona Deiana, Siro Bagnoli & Vito Annese. (2016) Development, safety, and efficacy of biosimilar adalimumab: the data so far. Biosimilars 6, pages 1-7.
Read now
Read now
Hans-Peter Hofmann, Ulrich Kronthaler, Cornelius Fritsch, Roger Grau, Stefan O. Müller, Robert Mayer, Andreas Seidl & Antonio Da Silva. (2016) Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel®). Expert Opinion on Biological Therapy 16:10, pages 1185-1195.
Read now
Read now
Alain Beck & Janice M. Reichert. (2013) Approval of the first biosimilar antibodies in Europe. mAbs 5:5, pages 621-623.
Read now
Read now
Articles from other publishers (7)
Róisín O’Flaherty, Adam Bergin, Evangelia Flampouri, Letícia Martins Mota, Ismael Obaidi, Andrew Quigley, Yongjing Xie & Michael Butler. (2020) Mammalian cell culture for production of recombinant proteins: A review of the critical steps in their biomanufacturing. Biotechnology Advances 43, pages 107552.
Crossref
Crossref
Stephen R Chapman, Raymond W Fitzpatrick & Mohammed I Aladul. (2017) Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey. BMJ Open 7:6, pages e016730.
Crossref
Crossref
Stephen R Chapman, Raymond W Fitzpatrick & Mohammed I Aladul. (2017) What drives the prescribing of growth hormone preparations in England? Prices versus patient preferences. BMJ Open 7:4, pages e013730.
Crossref
Crossref
Frank R. Brennan, Andreas Baumann, Guenter Blaich, Lolke de Haan, Rajni Fagg, Andrea Kiessling, Sven Kronenberg, Mathias Locher, Mark Milton, Jay Tibbitts, Peter Ulrich & Lucinda Weir. (2015) Nonclinical safety testing of biopharmaceuticals – Addressing current challenges of these novel and emerging therapies. Regulatory Toxicology and Pharmacology 73:1, pages 265-275.
Crossref
Crossref
Lilian Rumi Tsuruta, Mariana Lopes dos Santos & Ana Maria Moro. (2015) Biosimilars advancements: Moving on to the future. Biotechnology Progress 31:5, pages 1139-1149.
Crossref
Crossref
M. Rinaudo-Gaujous, S. Paul, E. D. Tedesco, C. Genin, X. Roblin & L. Peyrin-Biroulet. (2013) Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Alimentary Pharmacology & Therapeutics 38:8, pages 914-924.
Crossref
Crossref
Alain Beck, Hélène Diemer, Daniel Ayoub, François Debaene, Elsa Wagner-Rousset, Christine Carapito, Alain Van Dorsselaer & Sarah Sanglier-Cianférani. (2013) Analytical characterization of biosimilar antibodies and Fc-fusion proteins. TrAC Trends in Analytical Chemistry 48, pages 81-95.
Crossref
Crossref